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While there has been extensive attention to the ‘demand side’ – or use and adverse consequences, including mortality –
of the ‘opioid crisis’ presently unfolding across North America, few considerations have focused on the supply side. This
paper examines the supply side dynamics of this unprecedented public health phenomenon. We provide evidence for
several interrelated supply-side elements that have contributed to the present public health crisis. We observe that
initially, persistently high levels of prescription opioid availability and use exposed large proportions of the North
American population to opioids, resulting in correspondingly high levels of medical and non-medical use (e.g., involving
diversion). While various intervention measures to control prescription opioid availability and use have been implemented
in recent years, leading to eventual reductions in opioid dispensing levels, these occurred late in the crisis’s evolution.
Moreover, these supply reductions have not been met by corresponding reductions in opioid use or demand levels.
These growing discrepancies between opioid demand and prescription-based sources have left major gaps in opioid
supplies. In response to such supply gaps, highly potent and toxic illicit opioid products have rapidly proliferated across
North America, and become a core driver of the dramatic spikes in opioid overdose fatality levels in recent years. These
supply-related interrelations are corroborated by a corresponding increase in illicit opioid-related fatalities, which arose just
as medical opioid supplies began to decrease in many jurisdictions. Improved analyses and understanding of the supply-
side dynamics of the opioid crisis are urgently needed in order to inform future intervention and policy development.
Meanwhile, the high mortality toll related to illicit, highly toxic opioid exposure requires sustained solutions, including
supply-oriented measures (e.g., safer opioid distribution for at–risk users) towards improved public health protection.
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North America has been experiencing an unprecedented
public health crisis involving the non-medical use of opioid
drugs, and consequentially, a massive toll of accidental
opioid-related mortality (i.e., overdose). In 2018, there were
47,590 opioid-related deaths in the United States and a
corresponding 4,614 opioid-related deaths in Canada; a
threefold increase from a mere decade ago, [1, 2]. In both
countries, opioid-related mortality has led to discernable re-
ductions in life expectancy across the general population [3,
4]. Naturally, the lion’s share of scientific attention has been
devoted to examining risk factors or outcomes for© The Author(s). 2020 Open Access This artic
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measures in reducing deaths among opioid users (i.e., the
‘demand side’) [5–8]. Much less attention, however, has
been devoted to examining aspects of the ‘supply side’ of
this unprecedented public health crisis.Main text
The emergence of highly potent and toxic synthetic opi-
oid products (e.g., fentanyl and analogues) has been
identified as the distinct contributing factor to recent
spikes in opioid-related mortality in the United States
(U.S.) and Canada [9, 10]. These illicitly produced and
distributed opioid products have appeared and prolifer-
ated in North America only during recent (i.e., past five)
years, with many distributed as counterfeit prescriptionle is distributed under the terms of the Creative Commons Attribution 4.0
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other drug products (e.g., heroin or cocaine) which render
ready detection - either by consumers or law enforcement -
highly difficult [11, 12]. To illustrate: in Canada, the stee-
pest increases in recent opioid-related deaths have occurred
in the Western provinces, where over three quarters of
opioid-related deaths in British Columbia and Alberta have
involved fentanyl or fentanyl-analogues [13, 14]. In the
U.S., mortality related to synthetic opioids, despite
stark regional differences (e.g., increases in mortality
observed mainly in the North-Eastern states), has
risen by approximately 300% between 2013 and 2017,
far outpacing deaths related to other opioids in the
years following 2015 [15]. Synthetic opioids, primarily
in the form of fentanyl, have also been detected in a
growing number of non-opioid-related overdoses, includ-
ing roughly half of all cocaine-related fatal overdoses in
the U.S. in 2017 [16]. In line with these dynamics, the
present opioid mortality crisis has been widely character-
ized as a ‘fentanyl’ epidemic, consequently implicating
synthetic opioid drugs as the primary culprit of the unpre-
cedented death toll, although their predominant role and
impact has been regionally inconsistent and heteroge-
neous across North America [10, 17].
An important challenge therefore remains in adequately
understanding the ‘supply side’ dynamics of the present
opioid death crisis. Illicit drug markets and related dynam-
ics are complex phenomena involving multitudinal factors,
many of which are difficult to dissect and understand yet
essential for evidence-based analysis and interventions [18].
One documented instance is the Australian ‘heroin
drought’, where a sudden shortage in the nation’s heroin
supply resulted in subsequent shifts to other non-opioid
illicit drug use and related harms during the mid-1990s [19,
20]. It has never been fully clear why the relatively robust
Australian heroin market was unable to adjust to the dis-
ruption of one supply channel [19]. Similarly, the supply
side dynamics of the North American opioid crisis - even
rudimentarily – do not seem to be well-examined or
-understood, and few efforts have sought to assess why and
how North American opioid markets were suddenly
flooded with a growing supply of synthetic opioids, result-
ing in substantial social and health-related harms. Has the
influx of synthetic opioids in the U.S. and Canada been an
independent event - a kind of ‘supply shock’ event driven
predominantly by factors external to the North American
markets? Or rather, were the observed shifts in drug supply
a response to existing domestic demand-side forces? Select
examinations have sought to explore this question, includ-
ing a ‘three-wave’ characterization of recent opioid supply,
yet findings seem to primarily emphasize evolutionary de-
velopments in international illicit opioid production and
distribution chains as the main drivers behind the opioid
crisis unfolding in North America [21, 22].Substantial evidence supports the former perspective,
namely that the recent 'wave' of toxic illicit opioid supply
has emerged as an interrelated consequence within pre-
existing opioid demand and supply dynamics. The broader
context of the phenomenon of increasing opioid-related
mortality in North America originally evolved in the early
2000s, centrally driven by substantial increases in
population-level dispensing of prescription (medical) opi-
oids, consequent increases in non-medical use, and related
morbidity and mortality [23]. Specifically, consumption
rates of prescription opioids (POs; in defined daily doses
[DDD] per population/day) rose by several magnitudes in
North America between 2001 and 2013, rendering the U.S.
and Canada the two countries with the highest levels of
opioid consumption globally [24]. During peak years of
medical PO availability, between 2010 and 2012, as many
as one-in-five of general population adults reported annual
PO use, while approximately 5% were involved in annual
‘non-medical’ use [23]. Moreover, the prevalence of PO
use disorder in the U.S. general population increased by
50% between 2003 and 2013, to about 1% of the general
population [25]. Taken together, these data illustrate the
realities of the persistently flush PO environments in North
America, fuelled largely by extensive medical system-based
dispensing of opioids. Aside from vastly broadening the
population base of opioid users, these developments fur-
ther led to paradigmatic shifts in the supply path for non-
medical opioid use during the early 2000s. While local her-
oin markets, and use continued to exist in select locations,
heroin was largely replaced with medically sourced or
diverted POs in the early 2000s even among marginalized
(e.g., street-involved) users, as documented by several
North American field studies [26, 27]. This shift centrally
included slow-release oxycodone (e.g., Oxycontin) but also
other commonly available medical PO products, such as
fentanyl, hydromorphone, and hydrocodone formulations.
These distinct increases in medically sourced or
diverted opioid product supplies in North America were
gradually reflected in patterns of drug-related mortality.
Both the U.S. and Canada began experiencing substantial
increases in opioid-related deaths due to PO-related fa-
talities between 2002 and 2012 [23, 28, 29], with several
epidemiological examinations demonstrating strong cor-
relations between population-levels of dispensing and
mortality related to individual PO formulations during
this period [30–32]. Within merely a decade, large por-
tions of the North American population across all socio-
economic strata had become habituated into medical
and non-medical opioid use, and as a dire consequence,
both Canada and the U.S. experienced sharply increas-
ing levels of opioid-related morbidity (e.g., emergency
room admissions, opioid dependence diagnoses) and
overdose-related deaths unseen elsewhere in the world
[23, 33, 34].
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systems began to more actively respond to the emerging
PO-related crisis, enacting and/or reinforcing a multitude
of interventions aimed at constraining the excessive levels
of PO-related harms [5, 35]. Such measures included, for
example, new and improved prescription monitoring sys-
tems to detect over-use and -prescribing, the introduction
of ‘abuse deterrent’ opioid formulations, restrictions (e.g.,
formulary-based) on opioid availability, revised (more re-
strictive) opioid prescribing guidelines and enforcement
measures to target sources of overprescribing and diversion
(e.g., ‘pill mills’) among others [6, 36–38]. While it is impos-
sible to attribute precise effects to individual measures,
these actions have jointly led medical PO dispensing levels
to plateau or decline across select North American jurisdic-
tions post-2012 [39, 40]. Concretely, based on several data
sources, population levels of PO-dispensing declined by
about 20% in Canada [40], and about half of all provinces –
notably those with subsequently high numbers of illicit
opioid-related mortality – experienced substantially greater
declines post-2010 [40, 41]. Correspondingly, PO
dispensing in the US (e.g., as measured in morphine equiva-
lents) declined by similar proportions, between 2010 and
2016, although with substantially heterogeneous inter-state
patterns [42]. While globally, North America remained the
regional leader in PO consumption, medical opioid
availability and dispensing became increasingly more re-
strained and strictly monitored, naturally translating into
decreased availability and diversion potential for non med-
ical opioid use. This left multiple but large sub-groups of
individuals with demand for opioids with shrinking supplies
of non-medical access to opioids, including those with main
motives to control pain as well as those with of non-
medical use. A concurrent indicator of declining supplies
has been the price-levels of diverted POs, which rose sub-
stantially in many North American settings [43, 44]. Im-
portantly, however, the population-level demand for
opioids, and levels of non-medical or problematic opioid
use, did not correspondingly decrease, but rather remained
elevated or continued to climb [25, 45, 46]. Availability of
and engagement in treatment for opioid disorders have
seen substantial expansions in North America over the past
decade, yet these observations have been limited to minor-
ity sub-populations actively seeking and engaging in treat-
ment and rehabilitation, leaving sizeable non-medical user
populations exposed to the overall contractions in opioid
supply [46, 47].
It is around this period of increasing restraints on
POs, from about 2012 onwards, when illicit and dis-
tinctly potent toxic opioid products (e.g., fentanyl and
analogues) initially emerged to make their mark on
North American drug markets, with correspondingly ris-
ing impact on drug mortality outcomes [48–51]. More
likely and plausible than not, this occurred in directresponse to the shrinking supplies in non-medical PO
products. Despite indications of a resurgence in heroin
availability in many (but not all, and mainly focused on
those with previously established, viable heroin markets)
regions across North America following the implementa-
tion of the above described opioid control measures, in-
cluding evidence that global opium and heroin production
(e.g., in Mexico, Asia) appeared to re-expand post-2010,
these developments overall were unlikely to sufficiently
compensate for the emerging supply gaps to feed existent
demand for non-medical opioid use [21, 52, 53]. Multiple
epidemiological studies since 2010 have illustrated pre-
dominant trajectories of opioid use, mainly from initial
non-medical PO to illicit opioid use, commonly involving
transitions from non-injecting to injection use, in key sub-
populations [54–56]. Among other adverse health risks
and outcomes, rising incidences of infectious disease (e.g.,
Hepatitis C Virus) transmissions have been observed in
some settings, especially among younger injection opioid
users with a history of non-medical PO use [57–60]. While
contracting supplies and the need for more ‘cost-effective’
administration routes more commonly led to opioid use by
injection, however, the socio-behavioral profiles of many
non-medical opioid users in North America (e.g., involving
many non-marginalized users with principally PO-based
trajectories) have been such that typical routes of heroin
usage (e.g., injection or smoking) presumably were not uni-
versally realistic or desirable options [61–65]. Time-trend
data for opioid-related mortality in U.S. (Fig. 1) and the
Canadian provinces of Ontario (Fig. 2) and British
Columbia (Fig. 3) suggest that overdose fatalities related to
illicit opioid products began to increase just as medical PO
supplies, and related mortality, began to inflect towards
decreasing trends across North America. These trend
observations lend supporting evidence to the suggestion
of possible lateral, substitutive shifts in supply from one
opioid category to the other.
There are various case studies and – with some pre-
senting counter-factual scenarios - that provide plausibly
supporting evidence for the explanatory observations of-
fered. For example, within Canada, the province of Que-
bec has traditionally featured substantially lower – by up
to a three-fold magnitude - levels of PO dispensing com-
pared to all other provinces, and consequently lower
population-level exposure to POs [40, 74, 75]. Notably,
Quebec has not seen the dramatic increases in opioid-
related mortality, nor in levels of illicit opioid related
deaths experienced elsewhere in North America [2].
Similarly, other Anglo-Saxon countries with relatively
lower PO consumption levels (e.g. Australia, New Zea-
land, United Kingdom) have not experienced the ex-
treme spikes in opioid mortality that have been observed
in the U.S. and Canada [70, 76–79]. Yet, there remains
potentially inconsistent evidence that is difficult to
Fig. 1 Opioid prescriptions and opioid-related mortality in the United States, 2003–2017 [66, 67]
Fig. 2 Opioid dispensing and opioid-related mortality in Ontario (Canada), 2003–2017 [40, 68]
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Fig. 3 Opioid dispensing and opioid-related mortality in British Columbia (Canada), 2003–2017 [40, 69]
Fischer et al. Substance Abuse Treatment, Prevention, and Policy           (2020) 15:14 Page 5 of 8reconcile with the perspectives presented. For example,
mortality related to synthetic opioids has barely in-
creased in select U.S. states such as Washington and
Oregon - two jurisdictions with traditionally high PO
dispensing levels and direct geographical proximity to
British Columbia, Canada, an epicentre of synthetic opi-
oid mortality in North America [52]. However, there
may indeed exist regionally distinct and separate market
dynamics for opioid supply between these jurisdictions
despite their geographic proximity.
In the above, we have presented evidence and potential
explanatory frameworks to examine the supply side dy-
namics of the unprecedented opioid mortality epidemic as
has been unfolding across North America. A substantial
body of data suggests that the current crisis, with excessive
numbers of deaths related to synthetic opioids, ought to be
understood as an evolutionary consequence of prolonged
high PO availability and exposure, followed by substantial
restrictions in availability in the context of persistent non-
medical opioid use demand at the population level. Likely,
these restrictive interventions implemented over the past
decade have resulted in growing PO supply gaps in spite of
persistent demand, and that were compensated for
through an influx of highly potent and toxic illicit opioid
products. Notably, while opioid overdose fatality levels
have risen steeply due to illicit opioid products in recent
years, this does not necessarily imply an expansion in the
volume of high-risk opioid use or overdose incidents. Ra-
ther, the likelihood of overdose incidents and fatalityoutcomes has likely become elevated through the use of
highly potent and toxic opioid products [8, 21, 48, 52].
Given the relative ease of clandestine chemical produc-
tion and distribution by the creative and adaptive forces
behind illicit drug production and supply, it surely re-
quired little ingenuity to effectively recognize and respond
to these extensive demands for opioid supply, especially in
regions of North America where demand for prescription
opioid products for non-medical use had been persistently
high for long periods [11, 12, 71, 72]. Relevant analyses of
both toxicology and production and supply stream data
has suggested that a large proportion of the newly emer-
ging fentanyl and other synthetic opioid products origi-
nated mainly in both China and Mexico; from there,
facilitated by both relatively simple chemical production
processes, small drug quantities involved as well as inad-
equate monitoring and control of these trafficking activ-
ities, either final products or precursors for local
synthesizing were clandestinely shipped to and distributed
in North America [12, 72, 73, 80]. For exemplary seizure
data-based illustration coinciding with above-described
illicit opioid supply trends: The amounts of illicit fentanyl
products seized at US border entry-points rose from 1 kg
in 2013 to 675 kg in 2017; reports of drug enforcement sei-
zures containing fentanyl submitted to state and local la-
boratories increased from 978 (2013) to 34,000 (2016) [81].
If valid – and rigorous (e.g., epidemiological modelling)
analyses ought to further examine these proposed scenar-
ios of the dynamic interplay between different strands of
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and the various catastrophic adverse health consequences,
in North America – this implies at least two main insights.
First, we need to improve our analytical understanding of
psychoactive drug markets and their dynamics, especially
when both medical and illicit drug products are involved,
also because a selective and narrow focus on interventions
addressing a single supply source is likely to lead to un-
anticipated supply alternatives [82, 83]. This appears espe-
cially so when the corresponding ‘demand’ side has not
been effectively contained, as has been the case in the
present North American crisis scenario. Second, while ex-
cessive PO availability had existed in North America for a
rather long time, most interventions to curtail these came
rather (too) late and/or were insufficient [6]. Certainly, few
observers anticipated that PO supplies for non-medical use
would be replaced so quickly by an ample availability of
exceptionally potent and toxic, illicit opioid products.
Conclusions
It is becoming increasingly clear that ‘supply side’ con-
siderations are not only essential for our understanding
of the present opioid crisis, but also essential for inform-
ing effective interventions and solutions delivered on the
ground. Concretely, while multiple, extensive ‘demand
side’ interventions targeting non-medical opioid use and
its adverse health risks (such as naloxone distribution
programs, safer consumption facilities, opioid agonist
treatment options) have been implemented and ex-
panded, and there is substantial room for further scale-
up and select additional intervention programming (e.g.,
ED-based pharmacotherapy treatment provision or re-
ferral [84, 85], their overall impact in reducing opioid-
related harms likely has reached natural limits in the
persistent high-risk environment dominated by highly
toxic, synthetic opioids [7, 8, 52]. Core evidence for this
includes persistently high rates of opioid-related mortal-
ity across North America [86, 87] combined with socio-
behavioral data that, for example, in Canadian locales a
majority of opioid-related overdose fatalities occur
among individuals using drugs alone where they cannot
readily be assisted by emergency measures like naloxone
provision [62]. While innovative treatment interventions
like injection opioid (heroin)-assisted maintenance ther-
apy – originally initiated in Europe and offered in a few
select, small-scale Canadian programs [88–90] – may
serve small sub-groups of high-risk patients, scalable,
large-scale ‘safer opioid supply’ interventions are re-
quired as complementary intervention strategies to
mainly behavior- or environment-focused measures for
non-medical opioid users at high risk of exposure to
illicit, toxic products [8, 52, 91]. Such ‘safer opioid sup-
ply’ measures – some of which are proceeding on a
local, experimental basis (e.g. in Vancouver) – wouldprovide medical grade opioids products mainly aiming
to prevent and replace the use of illicit, toxic opioid
products [92, 93]. While this reminds of past consider-
ations on the possible public health benefits of POs re-
placing illicit opioid use, such ‘emergency measures’
need to be effectively combined with simultaneous com-
prehensive prevention measures for those many people
not currently involved in non-medical opioid use [94].
However, improved empirical understanding of the
causal supply dynamics and structures driving the
present opioid mortality crisis, and of non-medical drug
supply mechanics more generally, are urgently required
– if for nothing else than to better prevent such traged-
ies in the future. An estimated 250,000 lives lost to opi-
oids, and historic reversals in population-level life
expectancy for an entire generation of North Americans
in barely a decade should provide more than good and
sufficient reason for doing so.
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